Track II: Research Award Finalist Platform Presentations

2016 CPNP Program Committee
Disclosures of Interest

All relevant relationships have been mitigated.

Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Presentation-Specific Disclosure: Richard Silvia's presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: I will not be discussing specific drug therapies much during my presentation, but I may discuss some off-label uses of medications. These uses, while off-label, have been researched and are widely considered as acceptable treatments. One example would include the use of Prazosin for trauma-related nightmares. Emma Palmer's presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: Intranasal atomizer device for naloxone- non FDA approved device which may be discussed during presentation. Douglas Bogg's presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: delta-9-tetrahydrocannabinol.

It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.